Although an androgen deprivation therapy plus docetaxel regimen was shown to extend the survival of some patients with metastatic hormone-sensitive prostate cancer compared with androgen deprivation therapy alone, currently, there is no report in the literature investigating the impact of upfront docetaxel on subsequent first-line abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer. This study showed that their activity is maintained regardless of previous use of docetaxel for metastatic hormonesensitive prostate cancer. These findings can aid treatment decision-making. Background: The CHAARTED (ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) and STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trials showed that the addition of docetaxel (D) to androgen deprivation therapy (ADT) prolonged longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC). However, the impact of upfront D on subsequent therapies is still unexplored. As abiraterone acetate (AA) and enzalutamide (E) are the most commonly used first-line treatment for metastatic castration-resistant prostate cancer (mCRPC), we aimed to assess whether they maintained their efficacy after ADTþD versus ADT alone. Patients and Methods: A cohort of patients with mCRPC treated between 2014 and 2017 with first-line AA or E for mCRPC was identified from 3 hospitals' institutional review board-approved databases. Patients were classified by use of D for mHSPC. This time frame was chosen as ADTþD became a valid therapeutic option for mHSPC in 2014, and it inherently entailed a short follow-up time on AA/E. The endpoints included overall survival from ADT start, overall survival from AA/E start, and time to AA/E start from ADT start. Differences between groups were assessed using the log-rank test. Results: Of the 102 patients with mCRPC identified, 50 (49%) had previously received ADT alone, while 52 (51%) had ADTþD. No statistically significant difference in any of the evaluated outcomes was observed between the 2 cohorts. Yet, deaths in the ADTþD group were 12 versus 21 in the ADT alone, after a median follow-up of 24.4 and 29.8 months, respectively. Conclusion: In a cohort of ADT/ADTþD-treated patients with mCRPC with short times to first-line AA/E and follow-up, the efficacy of AA/E is similar regardless of previous use of D.
Introduction
Until recently, androgen deprivation therapy (ADT) by surgical or medical castration has been the standard-of-care for metastatic hormone-sensitive prostate cancer (mHSPC). 1 Upon progression, prostate cancer is termed castration-resistant, and chemotherapy and second-generation androgen receptor (AR) targeting agents, such as abiraterone acetate (AA) and enzalutamide (E), proven in clinical trials to increase longevity of men with metastatic castrationresistant prostate cancer (mCRPC), are used in patients deemed fit. [2] [3] [4] In this regard, a recent analysis of prescriptions in the United
States reported that AA and E are the preferred (76%) first-line therapy for men with mCRPC. 5 Recently, 2 new regimens combining ADT with docetaxel (D) and AA, respectively, have shown a survival advantage compared with ADT alone and have become new valid therapeutic options for the patient with mHSPC. [6] [7] [8] [9] Particularly, the chemohormonal combination showed a clear benefit for men with mHSPC with high-volume disease compared with ADT alone and has been introduced in the treatment paradigm of mHSPC in 2014. However, to date, there is no report in the literature evaluating the impact of early D on subsequent first-line AA or E for mCRPC, and an optimal sequence of drugs after progression on ADTþD does not exist. 6 Based on the similar HR data, we postulated that first-line AA or E for mCRPC at least maintained efficacy after ADTþD versus ADT alone. The biological rationale for this hypothesis is that early D debulks AR-independent tumor cells that would otherwise thrive under the positive selective pressure exerted by ADT alone and thus enhances the efficacy of AR-targeting AA or E as first-line treatment for mCRPC. 6, 10 Determining the impact of early D for mHSPC on subsequent AA/E therapy would greatly aid treatment decision-making and provide useful data to delineate the most appropriate sequence of drugs for a given patient after failure of the chemohormonal regimen. Therefore, in this report, we aimed to evaluate the outcomes of first-line AA or E treatment for patients with mCRPC selected from 3 hospitals' databases and classified by use of D for mHSPC.
Patients and Methods
From the Dana-Farber Cancer Institute of Boston, the St Vincent's Hospital of Sydney, and the Tom Baker Cancer Centre of Calgary Institutional Review Board-approved databases, we retrospectively identified consecutive patients with histologically confirmed and radiologically evaluable mCRPC who had initiated AA or E as first-line treatment for mCRPC between 2014 and 2017. This time frame was selected considering that the chemohormonal regimen was recognized as a valid therapeutic option for mHSPC in 2014. Patients were excluded if they had received AA or E for any earlier stage of disease or had been given any other agent as first-line treatment for mCRPC. The final cohort was classified by previous use of D for mHSPC into 2 groups: ADTþD and ADT alone. The primary endpoints of the study were overall survival (OS) from ADT start and OS from AA/E start, defined as time from ADT for mHSPC and time from first-line AA/E for mCRPC start, respectively, to death from any cause or censored at last follow-up visit. Time to AA/E start, defined as the interval from ADT commencement to initiation of first-line AA/E for mCRPC, was the secondary endpoint. The Kaplan-Meier method was used to estimate the distributions of the endpoints, including median time-toevent and its 95% CI, and the log-rank test was used to compare time-to-event distributions between the 2 groups. Time of metastatic disease presentation, whether after prior definitive local therapy or newly diagnosed (de novo), biopsy Gleason score, and follow-up data was collected from medical records.
Results
Overall, 102 patients with mCRPC were eligible for this analysis. Fifty-two (51%) had received ADTþD and 50 (49%) ADT alone, for mHSPC. Baseline patient characteristics are described in Table 1 . Despite randomization not being part of the study design, the 2 cohorts were well-balanced in terms of prior local therapy/de novo, median follow-up, and distributions of AA and E, which were similar also in the total population (50% vs. 47%, respectively). Most patients (71%) had de novo disease, and of the 53 with available data, 37 had biopsy Gleason score 8. Median follow-up was only 26.4 months (95% CI, 24.0-29.9 months) owing to the chosen eligibility time window. For the same reason, time to AA/E start was also short at 11.0 months (95% CI, 8.5-13.7 months) for the ADT-alone cohort and 12.8 months (95% CI, 11.1-15.7 months) for the ADTþD cohort (Table 2) . In this regard, no statistically significant difference was observed in time to AA/E start between the 2 study groups (P ¼ .7265). Furthermore, the 2 cohorts did not show any significant difference in OS from ADT start (P ¼ .2047) or in OS from AA/E start (P ¼ .6514) ( 
Discussion
Although the addition of D to ADT proved to be significantly beneficial for men with mHSPC, 6,7 the impact of upfront D on later therapies has not been yet investigated, and an optimal treatment sequence for mCRPC has not been defined by well-powered prospective trials, even for patients receiving D in the standard setting. In a recent analysis, second-generation hormonal agents AA and E have been reported as the most commonly administered firstline treatment for men in the United States with mCRPC. 5 To our knowledge, this retrospective study is the first to explore the influence of early D on the clinical efficacy of subsequent first-line AA or E for mCRPC, using contemporaneous cohorts of ADTþD and ADT-alone pretreated men with mCRPC. It has been theorized that early chemotherapy disposes of AR-independent tumor clones; 
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hence, favoring efficacy of AR targeting AA/E as first-line treatment for mCRPC. 6, 10 On the other hand, a few in vivo and in vitro studies observed cross-resistance between D for mCRPC, and subsequent AA or E and partly attributed it to the partially overlapping mechanisms of action of these drugs, which interfere with AR signaling pathway and inhibit AR nuclear translocation. [13] [14] [15] In the present study, D is used for the hormone-sensitive disease, but the treatment sequence is the same; hence, cross-resistance could arise. However, this report showed that first-line AA or E therapy for mCRPC maintains its activity whether D was used upfront or not. Specifically, there was no statically significant difference in any of the explored outcomes. Nonetheless, it should be noted that, in the ADT-alone group, OS from AA/E start was considerably shorter at 17. Furthermore, OS from ADT start was short at 33.5 months (95% CI, 22.4 months to NR) and consistent with a population with poor prognostic features. 8, 11, 12 Patients' baseline characteristics seem to support this premise, because 71% of the total population and 70% of the ADT alone cohort had de novo metastatic disease, and 37 of the 53 patients without missing data and, remarkably, 23 of 25 in the ADT-alone cohort had biopsy Gleason score 8. This is not surprising given the chosen recruitment time window, which inevitably determined a short median follow-up and a selection of patients with short times to AA/E start, which were 29.8 months (95% CI, 25.1-31.4 months) and 11.0 months (95% CI, 8.5-13.7 months) for the ADT-alone cohort, respectively. The present analysis is therefore heavily weighted by the early events, which were very similar in both arms, even in the pivotal studies that, as a matter of fact, required a longer follow-up for the benefits to be seen. As such, although the median survivals in the ADTþD group were not reached at the time of the analysis, there was no statistically significant difference from the ADT-alone group. Yet prostate cancer deaths were more numerous in the ADT-alone cohort compared with the ADTþD cohort (21 vs. 12 after a median follow-up of 29.8 and 24.4 months, respectively). This finding is visually highlighted by the Kaplan-Meier estimates of OS from ADT start, which show a gap between the curves starting after 15 months and quite steadily widening over time in favor of the combination group ( Figure 1A) . This also appears to be the case of OS from AA/E start ( Figure 1B) . Longer follow-up and possibly larger samples would be needed to confirm this trend. However, despite not reaching a statistically significant difference, men treated with the chemohormonal regimen tended to experience a longer time to AA/E start ( Figure 1C ) compared with those treated with ADT alone. Therefore, considering that the 2 study groups were well-balanced with respect to the number of patients and the clinical and treatment characteristics, we could speculate that patients who received upfront D appear to be faring better with first-line AA or E for mCRPC than patients who received ADT alone, which is consistent with our hypothesis. Larger prospective studies with longer follow-up and better biological and clinical patient characterization would be needed to confidently confirm this hypothesis. As the chemohormonal regimen is being increasingly administered to the population with mHSPC, gathering evidence on the most appropriate sequence of additional treatments after failure of upfront D has become paramount. To the authors' knowledge, the present analysis is the first to provide useful clinical data to address this issue. Nevertheless, the innate biases of this study, including the short median follow-up, small sample size, and retrospective nature, represent limitations that prevent generalization of the results. On the other hand, interpreted with caution, this data may aid the physician in treatment decision-making and reassure him on the use of early D for mHSPC. In fact, our outcomes showed that exposure to upfront D for mHSPC patients with poor prognostic factors, such as de novo metastatic presentation, at least does not reduce the efficacy of later AA/E used as first-line treatment for mCRPC. This conclusion is supported by the results of the latest post-hoc analysis of the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trial comparing 2 contemporaneously randomized cohorts of patients treated with ADTþD and ADTþAA, respectively. 18 Despite the limited statistical power and, similar to our study, a short follow-up (approximately 4 years), this report showed that the ADT plus AA significantly extends failure-free survival and progression-free survival compared with the chemohormonal regimen in the population with mHSPC. However, OS from randomization did not differ between the 2 treatment arms. Because most patients progressing after upfront D received AA or E, 18 it would appear that the activity of first-line AA or E for mCRPC was at least not diminished by previous use of D, as suggested by our analysis. Given the heterogeneity of prostate cancer, we deem it unlikely that a single sequence of treatments could provide the best benefit/ risk ratio to all patients with mCRPC progressing on early D. An individualized therapeutic approach that takes into account the diverse tumor biological and molecular features, patient clinical characteristics, and prognostic and predictive biomarkers would be required to maximize survival. However, although the continuous advances in the knowledge of tumor biology and in the development of biotechnologies pave the way towards a future of precision medicine, clinical reports addressing treatment sequencing questions can provide the clinician with useful indications to make evidencebased decisions.
Conclusion
Despite the shortcomings of this analysis, we deem our data clinically relevant as they suggest that, in a cohort of patients with short median follow-up and time to AA/E start, first-line AA/E treatment for mCRPC maintains its efficacy regardless of previous use of D for mHSPC.
Clinical Practice Points
AA and E are the most frequently used first-line treatment for mCRPC. In patients with mCRPC, the efficacy of AA/E seems to be similar regardless of previous use of D for mHSPC. Larger prospective studies with longer follow-up and better biological and clinical patient characterization are warranted to confirm these findings. These results may aid the physician in the treatment decisionmaking and reassure him on the use of early D for mHSPC.
